5739-98-0

Usage

Uses

Used in Pharmaceutical Development:
2-Hydroxy-6,7-dimethoxyquinoxaline is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structural features, including the methoxy and hydroxy groups, make it a versatile building block for the creation of new drugs with potential therapeutic applications.
Used in Biochemical Research:
In the field of biochemistry, 2-Hydroxy-6,7-dimethoxyquinoxaline is employed as a research tool to study the interactions of molecules with biological systems. Its lipophilic and hydrophilic properties allow it to be used in the investigation of cellular processes and the development of new biochemical assays.
Used in Pharmacological Studies:
2-Hydroxy-6,7-dimethoxyquinoxaline is utilized in pharmacological research to explore its potential as a therapeutic agent. Its chemical structure and properties make it a candidate for the development of new drugs that could be used to treat various diseases and medical conditions.

InChI:InChI=1/C10H10N2O3/c1-14-8-3-6-7(4-9(8)15-2)12-10(13)5-11-6/h3-5H,1-2H3,(H,12,13)

Upstream product

• 924-44-7 glyoxylic acid ethyl ester 
• 27841-33-4 4,5-dimethoxybenzene-1,2-diamine 
• 3395-03-7 4,5-dimethoxy-1,2-dinitrobenzene 

Downstream Products

• 216699-86-4 2-chloro-6,7-dimethoxyquinoxaline 
• 357637-43-5 6,7-dimethoxy-1-(4-methoxy-benzyl)-1H-quinoxalin-2-one 
• 221064-59-1 N-(2-Chloro-6-methylphenyl)-7,8-dihydroxyimidazo[1,5-a]quinoxalin-4-amine 
• 221063-10-1 N-(2-Chloro-6-methylphenyl)-7,8-dimethoxyimidazo[1,5-a]quinoxalin-4-amine 
• 357637-52-6 7,8-dimethoxy-5-(4-methoxy-benzyl)-5H-imidazo[1,5-a]quinoxalin-4-one 

Relevant academic research and scientific papers

COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS

The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 2: The synthesis and biological activities of RPR127963 an orally bioavailable inhibitor

RPR127963 demonstrates an excellent pharmacokinetic profile in several species and was found to be efficacious in the prevention of restenosis in a Yucatan mini-pig model upon oral administration of 1-5 mg/kg. The in vitro selectivity profile and SAR of t

Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: Improvement of cell potency

A series of anilino(imidazoquinoxaline) analogues bearing solubilizing side chains at the 6- and 7-positions of the fused phenyl ring has been prepared and evaluated for inhibition against Lck enzyme and of T-cell proliferation. Significant improvement of the cellular activity was achieved over the initial lead, compound 2.

Reaction of quinoxalin-2-ones with TosMIC reagent: Synthesis of imidazo[1,5-a]quinoxalin-4-ones

Imidazo[1,5-a]quinoxalin-4-ones were prepared in four steps starting from 1,2-phenylenediamines using a new strategy for the construction of the ring system. A key step in this new method involves the reaction of quinoxalin-2-ones with TosMIC (tosylmethyl isocyanide).